Recruiting studies: Resectable Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Phase 2 · 3 location(s) · University of California, San Diego · NCT06624475 Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245 Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127 DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235 Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Phase 2 · 1 location(s) · Morten Ladekarl · NCT05841420 Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)
Phase 3 · 3 location(s) · Rajiv Gandhi Cancer Institute & Research Center, India · NCT06712420 A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenoca
Phase 3 · 6 location(s) · Akeso · NCT07023315 IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635 A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464 AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05377658 Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CR
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06509568 Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149 Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Phase 2 · 1 location(s) · The First Affiliated Hospital of Guangzhou Medical Universit · NCT06926790 Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable
Phase N/A · 1 location(s) · Shanghai Zhongshan Hospital · NCT07054086 Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After R
Phase N/A · 1 location(s) · Liaoning Cancer Hospital & Institute · NCT06109454 Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Phase 2 · 12 location(s) · Fundacion Clinic per a la Recerca Biomédica · NCT07018947 Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07014150 Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcino
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161545 Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT04324151 A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
Phase 4 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06930573 Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Guangzhou Medical Universit · NCT06383728 Y-90 SIRT for Unresectable HCC Larger Than 7cm
Phase 2 · 2 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06707233 TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06487663 Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Phase 2 · 1 location(s) · Beijing Chest Hospital, Capital Medical University · NCT06467617 Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squa
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07147426 Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patie
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06576180 A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable I
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05967182 Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer
NA · 6 location(s) · University Hospital, Ghent · NCT06057766 Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
NA · 1 location(s) · RWTH Aachen University · NCT04996914 Intravital Microscopy in Human Solid Tumors
NA · 1 location(s) · Mayo Clinic · NCT03823144

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.